VJHemOnc Podcast

iwNHL 2022 Session I: Advances in the treatment of T-cell lymphoma

The 19th International Workshop on Non-Hodgkin Lymphoma (iwNHL) 2022 took place in Barcelona, Spain, and brought together leading experts in the field as they discussed several topics. In this podcast series, you will hear the latest updates in NHL and gain an insight into the sessions that took place at this year's meeting.

The first session from iwNHL focused on advances in the treatment and management of T-cell lymphoma. In this podcast, Laurence de Leval, MD, PhD, Lausanne University Hospital, Lausanne, Switzerland, Steven Horwitz, MD, PhD, Memorial Sloan-Kettering Cancer Center, New York, NY, François Lemonnier, MD, Henri Mondor University Hospital, Créteil, France, and David Sibon, MD, PhD, Henri Mondor University Hospital, Créteil, France, discuss the safety and efficacy of brentuximab vedotin in enteropathy-associated T-cell lymphomas (EATL), epigenetic drugs and TRBC1-directed CAR-T therapy in T-cell lymphoma, and novel developments in the field of cutaneous T-cell lymphoma (CTCL). 

ISA 2022: meeting highlights and recent updates in amyloidosis

The 18th Meeting of the International Society of Amyloidosis (ISA) was held in Heidelberg, Germany, on 4-8 September, 2022. This meeting brought together experts in amyloidosis as they discussed the latest updates in the field, including novel therapeutic approaches, clinical trial updates, and recent advances in the diagnosis and management of this disease.

In this exclusive podcast, you will hear from experts Shaji Kumar, MD, Mayo Clinic, Rochester, MN, and Ashutosh Wechalekar, MBBS, MD, FRCP, FRCPath, DM, University College London, London, UK, as they share their highlights from this year's meeting. Topics covered in this podcast include the evolution of diagnostic approaches in light chain (AL) amyloidosis, advances in imaging techniques, and the role of hematopoietic stem cell transplantation (HSCT) in the era of daratumumab-based therapies. 

Highlights from IMS 2022: managing high-risk & frail patients with myeloma and the prognostic value of MRD

The 19th International Myeloma Society (IMS) Annual Meeting was held in Los Angeles, CA, and brought together experts in the field, who discussed several fascinating topics, including novel treatment strategies in multiple myeloma, the prognostic value of measurable residual disease (MRD), managing patients with high-risk disease, and more. 

In this exclusive podcast, Charlotte Pawlyn, BA, MBBChir, MRCP, PhD, FRCPath, The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, London, UK, and Rakesh Popat, BSc, MBBS, MRCP, FRCPath, PhD, University College London Hospitals NHS Foundation Trust, London, UK, hold a fascinating discussion on the management of high-risk patients, highlighting data from several UK clinical trials. The experts also discuss the prognostic value of MRD and its application in clinical practice, the management of frail patients, and further comment on the recent approval of teclistamab by the European Medicines Agency (EMA). 

Highlights from the 2022 Texas MPN Workshop: early intervention, disease progression & future targets

The 2022 Texas MPN Workshop was held in San Antonio, TX, and covered several fascinating topics in the field of myeloproliferative neoplasms (MPNs). MPNs represent a heterogeneous group of diseases that remain a challenge to diagnose and treat. Several experts agree that early intervention and better understanding disease progression are crucial aspects to consider when treating patients, and studies investigating this are underway.

In this exclusive podcast, you will hear from experts Andrew Kuykendall, MD, H. Lee Moffitt Cancer Center, Tampa, FL, and Angela Fleischman, MD, PhD, University of California Irvine, Irvine, CA, as they share some insights into disease progression in MPNs, the importance of early intervention, and future targets.

iwMDS 2022: Key highlights

The 1st International Workshop on Myelodysplastic Syndromes (iwMDS) 2022 was held in Miami, FL, and brought together leading experts in MDS who discussed the latest updates in the field. Several fascinating topics were covered at this year's meeting, including immune dysregulation and targeting in MDS, improving the efficiency of drug approvals, treating high-risk disease, and more. 

In this podcast, Amer Zeidan, MBBS, Yale School of Medicine, New Haven, CT, Rena Buckstein, MD, FRCPC, Sunnybrook Health Sciences Centre, Toronto, Canada, and Valeria Santini, MD, University of Florence, Florence, Italy, share key highlights from this year's workshop. The experts comment on the importance of improving clinical trial design and therapeutic options for patients, as well challenges in the field. 

Identifying high-risk myeloma and improving treatment strategies in these patients

Multiple myeloma is a heterogeneous disease, and despite recent advances in therapeutic agents, several patients still relapse after therapy and have poor survival outcomes. The identification of high-risk features, including the presence of del(17p) and t(4;14), are crucial for improving diagnosis and outcomes for these patients. 

In this podcast, Heinz Ludwig, MD, Wilhelminen Cancer Research Institute, Wilhelminenspital, Vienna, Austria, and Meral Beksac, MD, Ankara University, Ankara, Turkey, hold a fascinating discussion on identifying high-risk myeloma patients, and parameters that can be used to define high-risk disease. The experts also comment on treatment strategies for this patient population, emphasizing the promise of CAR-T therapy and bispecific antibodies. This discussion took place at the 19th International Myeloma Society (IMS) Annual Meeting held in Los Angeles, CA.

Improving the efficiency of drug approvals in MDS

In recent years, the treatment and management of myelodysplastic syndromes (MDS) has improved, and several clinical trials are investigating novel combinations and agents with the aim of providing more options for patients. Due to the heterogeneity of this disease, there are several challenges with treating MDS, and a need to improve the availability of therapeutic agents.

In this podcast, leading experts Hetty Carraway, MD, Cleveland Clinic, Cleveland, OH, Justin Taylor, MD, Sylvester Comprehensive Cancer Center, Miami, FL, Andrew Brunner, MD, Massachusetts General Hospital, Boston, MA, and Olatoyosi Odenike, MD, UChicago Medicine, Chicago, IL, share their thoughts on how to improve the efficiency of drug approvals in MDS. The experts cover several interesting topics, including the challenges associated with treating high-risk disease, novel targets of interest, and more. This discussion took place at the 1st International Workshop on Myelodysplastic Syndromes (iwMDS) held in Miami, FL.

Highlights from the 2022 Texas MPN Workshop: advances in MPN treatment

Myeloproliferative neoplasms (MPNs) represent a group of rare and heterogeneous diseases which remain a challenge to treat. Several advances have been made in recent years, both in the diagnosis and treatment of MPNs. The 2022 Annual Texas MPN Workshop brought together leading experts in the field, who discussed current and future treatment strategies, ongoing clinical trials, and future outlooks. 

In this exclusive podcast, leading experts Ruben Mesa, MD, UT Health San Antonio MD Anderson Cancer Center, San Antonio, TX, and Naveen Pemmaraju, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, share key updates in the treatment and management of essential thrombocythemia (ET), polycythemia vera (PV), and myelofibrosis (MF), and more highlights from this year's meeting.

The need for more effective first-line therapies in MDS

The treatment and management of myelodysplastic syndromes (MDS) remains a challenge due to the heterogeneity of the disease, and early diagnosis and intervention are important factors in MDS. Several experts agree that there is a need to develop more effective first-line therapies, and numerous clinical trials are exploring novel agents and combinations that may improve patient outcomes.

In this exclusive podcast, you will hear from Uwe Platzbecker, MD, University of Leipzig, Leipzig, Germany, Daniel Starczynowski, PhD, Cincinnati Children’s Hospital, Cincinnati, OH, Naval Daver, MD, University of Texas MD Anderson Cancer Center, Houston, TX, and David Sallman, MD, Moffit Cancer Center, Tampa, FL, who share their thoughts on why there are fewer treatment options for MDS patients compared to other hematological malignancies, the promise of CAR-T therapy and CD47 antibodies in MDS treatment, and more. 

Myeloma 2022: day two highlights

There were several fascinating sessions and discussions at the Myeloma 2022 meeting that took place in Scottsdale, AZ. Topics that were covered include: the role of genomics in the age of immuno-oncology, novel targets and agents, T-cell engagers, and resistance to immunotherapies. 

In this podcast, Gareth Morgan, MD, PhD, FRCP, FRCPath, NYU Langone Health, New York, NY, Rafael Fonseca, MD, Mayo Clinic, Phoenix, AZ, Leif Bergsagel, Mayo Clinic, Phoenix, AZ, and Keith Stewart, MB, ChB, Princess Margaret Cancer Centre, Toronto, Canada, share their highlights from day two of the Myeloma 2022 meeting. The experts cover several topics, including the biology behind BCL2 inhibitors, T-cell exhaustion and its role in resistance to immunotherapies, and more.